TY - JOUR
T1 - Patients benefit from genetics-guided coumarin anticoagulant therapy
AU - Maitland-Van Der Zee, A. H.
AU - Daly, A. K.
AU - Kamali, F.
AU - Manolopoulous, V. G.
AU - Verhoef, T. I.
AU - Wadelius, M.
AU - De Boer, A.
AU - Pirmohamed, M.
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Observational studies have overwhelmingly shown that variants in the genes CYP2C9 and VKORC1 are significant determinants of individual dose of coumarin anticoagulants needed to maintain a therapeutic international normalized ratio (INR). 1 Until recently, however, few randomized clinical trials had been performed relating to the use of genetic data to predict dosing. Three sucsh clinical trials have now reported their findings.
AB - Observational studies have overwhelmingly shown that variants in the genes CYP2C9 and VKORC1 are significant determinants of individual dose of coumarin anticoagulants needed to maintain a therapeutic international normalized ratio (INR). 1 Until recently, however, few randomized clinical trials had been performed relating to the use of genetic data to predict dosing. Three sucsh clinical trials have now reported their findings.
UR - http://www.scopus.com/inward/record.url?scp=84902689256&partnerID=8YFLogxK
U2 - 10.1038/clpt.2014.44
DO - 10.1038/clpt.2014.44
M3 - Article
C2 - 24942396
AN - SCOPUS:84902689256
SN - 0009-9236
VL - 96
SP - 15
EP - 17
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
IS - 1
ER -